Clinical Trials Logo

Type 2 Diabetes Mellitus (T2DM) clinical trials

View clinical trials related to Type 2 Diabetes Mellitus (T2DM).

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06327815 Recruiting - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Start date: March 27, 2024
Phase: Phase 4
Study type: Interventional

Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with Metformin XR in glycemic lowering control, satisfaction and adherence in Chinese patients with T2DM.

NCT ID: NCT06279234 Recruiting - Obesity Clinical Trials

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

Start date: February 20, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes mellitus (T2DM) on metformin (Part A) and optionally in non-diabetic participants with obesity (Part B).

NCT ID: NCT05761301 Recruiting - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Start date: March 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.

NCT ID: NCT05673668 Recruiting - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Endovascular Denervation (EDN) for the Treatment of Type 2 Diabetes Mellitus

Start date: December 27, 2022
Phase: N/A
Study type: Interventional

This is a prospective, single-center, single-arm, self-controlled study to evaluate the effects of endovascular denervation (EDN) on insulin secretory function and insulin sensitivity in the treatment of type 2 diabetes mellitus (T2DM) .

NCT ID: NCT05102149 Recruiting - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Start date: September 30, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, parallel, Vildagliptin and Placebo-Controlled study to evaluate the efficacy and safety of oral administration of 100 mg of PB-201 in the morning and evening in treatmentnaive patients with type 2 diabetes mellitus.

NCT ID: NCT04943861 Recruiting - HIV Clinical Trials

Human Immunodeficiency Virus (HIV) Food Insecurities

Start date: November 14, 2023
Phase: N/A
Study type: Interventional

The objectives of this study are to better understand how FI (food insecurities) contributes to the development of cardiometabolic comorbidities among PWH (People with HIV) and to test a novel bilingual FI intervention designed to reduce these comorbidities among food insecure PWH. The PI and staff will conduct this study in partnership with the Wake Forest Infectious Diseases Specialty Clinic, one of the largest Ryan White-funded clinics in North Carolina, which serves more than 2,000 PWH annually from a predominantly rural catchment area that includes South Central Appalachia. This area has high rates of both FI and HIV.

NCT ID: NCT04501406 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

NCT ID: NCT02002143 Recruiting - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

GMVs in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People

GAP
Start date: January 2014
Phase: N/A
Study type: Interventional

Type 2 diabetes is a major problem of older people; its prevalence is greater than 20% in those aged over 65 years. Treatment such as medication, healthy nutritional choices & body weight management, as well as physical activity can reduce the impact of diabetes. Older patients with type 2 diabetes can potentially benefit from Group Appointments, in which 8-12 patients share one appointment of about 60-120 minutes with a team of health professionals. The team of investigators (3 people) will see the 'Group' 4 times/yr for two years. Their key measure of success will be control of glycosylated hemoglobin - HbA1C. To address their primary and secondary research objectives the investigators will focus upon patients aged 65 years or older who have T2DM and who are being treated with oral hypoglycemic agents and diet, or diet alone. The investigators will compare patients randomized to (A) eight Group Appointments over a 24 month period (i.e., 4 per year), led by a primary care physician [Intervention] with, (B) patients randomized to eight traditional one-to-one usual care appointments also provided by a primary care physician (Individual Appointment; [Control]). The investigators will compare (A) and (B) on selected clinical, patient-rated, and economic outcome measures. SIGNIFICANCE: Seven Canadian provinces already have Group Appointment billing codes for physicians who lead Group Appointments. If the study's proposed health care innovation demonstrates benefits, it would be possible to 'roll out' / 'scale up' the model province- or nation-wide in Primary Care settings.